Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden

Clinical Therapeutics

Volumn 35, Issue 2, 2013, Pages 119-134

  Klok, Rogier M ^a   Lindkvist, Rose Marie ^a   Ekelund, Mats ^a   Farkouh, Raymond A ^a   Strutton, David R ^a  

^a PFIZER INC   (United States)

Author keywords

Cost effectiveness; Pneumococcal conjugate vaccine Prevenar13; Synflorix; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DENMARK; INCIDENCE; MORTALITY; PNEUMOCOCCAL INFECTION; SEROTYPE; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DENMARK; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; LIFE EXPECTANCY; MIDDLE AGED; MODELS, ECONOMETRIC; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84873581116     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.006     Document Type: Article

References (65)

1. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104. World Health Organization, Accessed April 26, 2010. http://www.who.int/immunization/wer8212pneumococcus_child_Mar07_position_paper.pdf.
2. Kilpi T., Ahman H., Jokinen J., et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003, 37:1155-1164.
3. Black S.B., Shinefield H.R., Hansen J., et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001, 20:1105-1107.
4. Grijalva C.G., Poehling K.A., Nuorti J.P., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118:865-873.
5. Rozenbaum M., Boersma C., Postma M., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011, 10:187-199.
6. Miller E., Andrews N., Waight P., et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
7. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
8. Grijalva C.G., Nuorti J.P., Arbogast P.G., et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
9. European Public Assessment Report, Prevenar pneumococcal saccharide conjugated vaccine, adsorbed European Medicines Agency, Accessed November 19, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000323/human_med_000987.jsp&mid=WC0b01ac058001d124.
10. European Public Assessment Report, Synflorix pneumococcal polysaccharide conjugate vaccine (adsorbed) European Medicines Agency, Accessed November 19, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&mid=WC0b01ac058001d124.
11. European Public Assessment Report, Prevenar 13 pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) European Medicines Agency, Accessed November 19, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/human_med_001220.jsp&mid=WC0b01ac058001d124.
12. Strutton D.R., Farkouh R.A., Earnshaw S.R., et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect 2012, 64:54-67.
13. Ingels H., Rasmussen J., Andersen P.H., et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine 2012, 30:3944-3950. Danish Pneumococcal Surveillance Collaboration Group 2009-2010.
14. Data on inpatient pneumonia over age groups in 2011 Statistics Denmark, Accessed November 29, 2012. http://www.dst.dk.
15. Stangerup S.E., Tos M. Epidemiology of acute suppurative otitis media. Am J Otolaryngol 1986, 7:47-54.
16. Epidemiologisk årsrapport 2010, Smittskyddsinstitutet Patientregistret, Socialstyrelsen 2011, Elanders Sverige AB, Stockholm, SE.
17. National Board of Health and Welfare, Accessed March 20, 2012. http://http://www.socialstyrelsen.se/Statistik/statistikdatabas.
18. Engström S., Mölstad S., Nilsson G., et al. Data from electronic patient records are suitable for surveillance of antibiotic prescriptions for respiratory tract infections in primary health care. Scand J Infect Dis 2004, 36:139-143.
19. Neumark T., Brudin L., Engstrom S., Molstad S. Trends in number of consultations and antibiotic prescriptions for respiratory tract infections between 1999 and 2005 in primary healthcare in Kalmar County, Southern Sweden. Scand J Prim Health Care 2009, 27:18-24.
20. By Å., Sobocki P., Forsgren A., Silferdal S.A. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther 2012, 34:177-189.
21. Gisselsson-Solén M., Melhus A., Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media-a randomized study. Acta Paediatr 2011, 100:1354-1358.
22. Life expectancy in Denmark over age groups, 2010 Statistics Denmark, Accessed June 20, 2012. http://www.dst.dk.
23. Statistics Sweden, Life expectancy by region, sex, observations and period (2007-2011) Accessed March 20, 2012. http://www.scb.se/.
24. Harboe Z.B. Studies on the Epidemiology of Invasive Pneumococcal Disease and Related Mortality in Denmark [doctoral thesis] 2010, University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark.
25. Danish cause of death registry in 2010 Statistics Denmark, Accessed November 29, 2012. http://www.dst.dk.
26. Dahl M.S., Trollfors B., Claesson B.A., et al. Invasive pneumococcal infections in south-western Sweden: a second follow up period of 15 years. Scand J Infect Dis 2001, 33:667-672.
27. Shinefield H.R., Black S., Ray P., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18:757-763.
28. Black S., Shinefield H., Baxter R., et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 2006, 24(Suppl 2):S2-S79. 80.
29. Vesikari T., Wysocki J., Chevallier B., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(Suppl 4):S66-S76.
30. Goldblatt D. Establishing the correlate for pneumonia. Presentation at: 6th International Symposium on Pneumococci and Pneumococcal Diseases June 11, 2008.
31. Ray G.T., Whitney C.G., Fireman B.H., et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:494-501.
32. Benfield T., Marlene S., Sørensen H.C., et al. Serotype distribution in non-bacteremic pneumococcal pneumonia: implications for pneumococcal conjugate vaccines. Poster presented at: the 8th International Symposium on Pneumococci and Pneumococcal Diseases March 11-15, 2012, Poster no. 515.
33. Fireman B., Black S.B., Shinefield H.R., et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
34. Prymula R., Peeters P., Chrobok V., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367:740-748.
35. Strutton D., Hwang S., Farkouh R., et al. Response to "outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.". Vaccine 2011, 29:7589-7590.
36. Talbird S., Knerer G., Hausdorff W., et al. Response to "outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.". Vaccine 2011, 29:7591-7592.
37. van Gils E.J., Veenhoven R.H., Hak E., et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009, 302:159-167.
38. Koshy E., Murray J., Bottle A., et al. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010, 65:770-774.
39. Nelson J.C., Jackson M., Yu O., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008, 26:4947-4954.
40. Zhou F., Kyaw M.H., Shefer A., et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007, 161:1162-1168.
41. Cohen R., Levy C., Bingen E., et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). Podium presentation at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2011.
42. Moore M., Link-Gelles R., Farley M., et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010-11. Presented at: the 8th International Symposium on Pneumococci and Pneumococcal Diseases March 11-15, 2012.
43. Moore M., Link-Gelles R., Farley M.M., et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, 2010-11. Session 1219. IDWeek 2012 (TM, annual scientific meeting on infectious diseases) October 17 - 21, 2012.
44. Prymula R., Kriz P., Kaliskova E., et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009, 28:71-78.
45. Prymula R., Hanovcova I., Splino M., et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011, 29:1959-1967.
46. van den Bergh M.R., Spijkerman J., Swinnen K.M., et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013, 56:e30-e39.
47. Oostenbrink R., Moll H.A., Essink-Bot M.L. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002, 55:791-799.
48. Maddigan S.L., Feeny D.H., Johnson J.A., et al. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005, 14:1311-1320.
49. Muciño-Ortega E., Mould-Quevedo J.F., Farkouh R., Strutton D. Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines [in Spanish]. Value Health 2011, 14(5 Suppl 1):S65-S70.
50. Tyo K.R., Rosen M.M., Zeng W., et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 2011, 29:6686-6694.
51. Robberstad B., Frostad C.R., Akselsen P.E., et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 2011, 29:8564-8574.
52. Knerer G., Ismaila A., Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ 2012, 15:61-76.
53. Farkouh R.A., Klok R.M., Postma M.J., et al. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines 2012, 11:1235-1247.
54. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409. Finnish Otitis Media Study Group.
55. Black S., Shinefield H., Ling S., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815.
56. Zhou F., Shefer A., Kong Y., Nuorti J.P. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008, 121:253-260.
57. Lieu T.A., Ray G.T., Black S.B., et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000, 283:1460-1468.
58. Lieu T.A., Ray G.T. Summary of updates and revisions to: projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. Presented at: CDC Advisory Review Panel May 29, 2000.
59. Prosser L., Ray G., O'Brien M., et al. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 2004, 113:283-290.
60. Palmu A.A., Jokinen J., Borys D., et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381:214-222. 19.
61. Whitney C.G., Pilishvili T., Farley M., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
62. Yeh S.H., Gurtman A., Hurley D.C., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126:e493-e505.
63. Kieninger D.M., Kueper K., Steul K., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28:4192-4203.
64. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148. Centers for Disease Control and Prevention.
65. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention.